Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions

Journal of Immunology

Volumn 191, Issue 1, 2013, Pages 353-362

  Stemerding, Annette M ^a,f   Köhl, Jörg ^b,c   Pandey, Manoj K ^c   Kuipers, Annemarie ^a   Leusen, Jeanette H ^a   Boross, Peter ^a   Nederend, Maaike ^a   Vidarsson, Gestur ^d   Weersink, Annemarie Y L ^a,g   Van De Winkel, Jan G J ^a,e   Van Kessel, Kok P M ^a   Van Strijp, Jos A G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e GENMAB   (Netherlands)

^f Gelre Ziekenhuizen ^*  (Netherlands)

^g MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR II; FLIPR LIKE PROTEIN; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; FORMYLPEPTIDE RECEPTOR LIKE 1 INHIBITOR; IMMUNOGLOBULIN G; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ARTHUS PHENOMENON; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR KILLING; LIGAND BINDING; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OPSONIZATION; OPSONOPHAGOCYTOSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN SECRETION; STAPHYLOCOCCUS AUREUS; TUMOR CELL;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BACTERIAL PROTEINS; BINDING SITES, ANTIBODY; HUMANS; IMMUNE EVASION; LEUKEMIA P388; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; PROTEIN BINDING; RECEPTORS, IGG; SEQUENCE HOMOLOGY, AMINO ACID; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84879632188     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203243     Document Type: Article

References (52)

1. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
2. Foster, T. J. 2005. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3: 948-958. (Pubitemid 43078158)
3. Rigby, K. M., and F. R. DeLeo. 2012. Neutrophils in innate host defense against Staphylococcus aureus infections. Semin. Immunopathol. 34: 237-259.
4. Vidarsson, G., A. M. Stemerding, N. M. Stapleton, S. E. Spliethoff, H. Janssen, F. E. Rebers, M. de Haas, and J. G. van de Winkel. 2006. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 108: 3573-3579.
5. Rooijakkers, S. H., and J. A. van Strijp. 2007. Bacterial complement evasion. Mol. Immunol. 44: 23-32. (Pubitemid 44647108)
6. Rooijakkers, S. H., M. Ruyken, A. Roos, M. R. Daha, J. S. Presanis, R. B. Sim, W. J. van Wamel, K. P. van Kessel, and J. A. van Strijp. 2005. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6: 920-927. (Pubitemid 43090447)
7. Jongerius, I., J. Köhl, M. K. Pandey, M. Ruyken, K. P. van Kessel, J. A. van Strijp, and S. H. Rooijakkers. 2007. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 204: 2461-2471.
8. Atkins, K. L., J. D. Burman, E. S. Chamberlain, J. E. Cooper, B. Poutrel, S. Bagby, A. T. Jenkins, E. J. Feil, and J. M. van den Elsen. 2008. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol. Immunol. 45: 1600-1611. (Pubitemid 351227405)
9. Smith, E. J., L. Visai, S. W. Kerrigan, P. Speziale, and T. J. Foster. 2011. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect. Immun. 79: 3801-3809.
10. Patel, D., B. D. Wines, R. J. Langley, and J. D. Fraser. 2010. Specificity of staphylococcal superantigen-like protein 10 toward the human IgG1 Fc domain. J. Immunol. 184: 6283-6292.
11. Deisenhofer, J. 1981. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 20: 2361-2370. (Pubitemid 11089772)
12. Rooijakkers, S. H., W. J. van Wamel, M. Ruyken, K. P. van Kessel, and J. A. van Strijp. 2005. Anti-opsonic properties of staphylokinase. Microbes Infect. 7: 476-484. (Pubitemid 40603446)
13. van de Winkel, J. G., and P. J. Capel. 1993. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 14: 215-221.
14. Nimmerjahn, F., and J. V. Ravetch. 2011. FcγRs in health and disease. Curr. Top. Microbiol. Immunol. 350: 105-125.
15. Hogarth, P. M., and G. A. Pietersz. 2012. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11: 311-331.
16. van Sorge, N. M., W. L. van der Pol, and J. G. van de Winkel. 2003. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61: 189-202.
17. Su, K., H. Yang, X. Li, X. Li, A. W. Gibson, J. M. Cafardi, T. Zhou, J. C. Edberg, and R. P. Kimberly. 2007. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178: 3272-3280. (Pubitemid 46333211)
18. Smith, K. G., and M. R. Clatworthy. 2010. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10: 328-343.
19. Peipp, M., J. J. Lammerts van Bueren, T. Schneider-Merck, W. W. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. van Berkel, T. Vink, J. G. van de Winkel, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
20. de Haas, C. J., K. E. Veldkamp, A. Peschel, F. Weerkamp, W. J. Van Wamel, E. C. Heezius, M. J. Poppelier, K. P. Van Kessel, and J. A. van Strijp. 2004. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial anti-inflammatory agent. J. Exp. Med. 199: 687-695. (Pubitemid 38316435)
21. Prat, C., J. Bestebroer, C. J. de Haas, J. A. van Strijp, and K. P. van Kessel. 2006. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J. Immunol. 177: 8017-8026. (Pubitemid 44846319)
22. Prat, C., P. J. Haas, J. Bestebroer, C. J. de Haas, J. A. van Strijp, and K. P. van Kessel. 2009. A homolog of formyl peptide receptor-like 1 (FPRL1) inhibitor from Staphylococcus aureus (FPRL1 inhibitory protein) that inhibits FPRL1 and FPR. J. Immunol. 183: 6569-6578.
23. Schneider-Merck, T., J. J. Lammerts van Bueren, S. Berger, K. Rossen, P. H. van Berkel, S. Derer, T. Beyer, S. Lohse, W. K. Bleeker, M. Peipp, et al. 2010. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 184: 512-520.
24. Lohse, S., S. Derer, T. Beyer, K. Klausz, M. Peipp, J. H. Leusen, J. G. van de Winkel, M. Dechant, and T. Valerius. 2011. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J. Immunol. 186: 3770-3778.
25. Godau, J., T. Heller, H. Hawlisch, M. Trappe, E. Howells, J. Best, J. Zwirner, J. S. Verbeek, P. M. Hogarth, C. Gerard, et al. 2004. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 173: 3437-3445. (Pubitemid 39142055)
26. Ierino, F. L., M. D. Hulett, I. F. McKenzie, and P. M. Hogarth. 1993. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors. J. Immunol. 150: 1794-1803. (Pubitemid 23129655)
27. Veri, M. C., S. Gorlatov, H. Li, S. Burke, S. Johnson, J. Stavenhagen, K. E. Stein, E. Bonvini, and S. Koenig. 2007. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121: 392-404. (Pubitemid 46817361)
28. Ravetch, J. V., and B. Perussia. 1989. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med. 170: 481-497. (Pubitemid 19204276)
29. Agniswamy, J., B. Lei, J. M. Musser, and P. D. Sun. 2004. Insight of host immune evasion mediated by two variants of group a Streptococcus Mac protein. J. Biol. Chem. 279: 52789-52796. (Pubitemid 39656655)
30. Dougherty, G. J., Y. Selvendran, S. Murdoch, D. G. Palmer, and N. Hogg. 1987. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. Eur. J. Immunol. 17: 1453-1459. (Pubitemid 17161200)
31. Woolhiser, M. R., K. Brockow, and D. D. Metcalfe. 2004. Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin. Immunol. 110: 172-180. (Pubitemid 38296707)
32. Tamm, A., and R. E. Schmidt. 1996. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J. Immunol. 157: 1576-1581. (Pubitemid 126449096)
33. Köhl, J., and J. E. Gessner. 1999. On the role of complement and Fc gamma-receptors in the Arthus reaction. Mol. Immunol. 36: 893-903.
34. Kurlander, R. J., D. M. Ellison, and J. Hall. 1984. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J. Immunol. 133: 855-862. (Pubitemid 14093480)
35. Söderberg, J. J., P. Engström, and U. von Pawel-Rammingen. 2008. The intrinsic immunoglobulin g endopeptidase activity of streptococcal Mac-2 proteins implies a unique role for the enzymatically impaired Mac-2 protein of M28 serotype strains. Infect. Immun. 76: 2183-2188.
36. McCarthy, A. J., and J. A. Lindsay. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 10: 173.
37. Langley, R., B. Wines, N. Willoughby, I. Basu, T. Proft, and J. D. Fraser. 2005. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J. Immunol. 174: 2926-2933. (Pubitemid 40279711)
38. Ye, R. D., F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy. 2009. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61: 119-161.
39. Nagarajan, S., K. Venkiteswaran, M. Anderson, U. Sayed, C. Zhu, and P. Selvaraj. 2000. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood 95: 1069-1077. (Pubitemid 30062733)
40. Nagarajan, S., N. H. Fifadara, and P. Selvaraj. 2005. Signal-specific activation and regulation of human neutrophil Fc gamma receptors. J. Immunol. 174: 5423-5432. (Pubitemid 40593182)
41. Kew, R. R., C. M. Grimaldi, M. B. Furie, and H. B. Fleit. 1992. Human neutrophil Fc gamma RIIIB and formyl peptide receptors are functionally linked during formyl-methionyl-leucyl-phenylalanine-induced chemotaxis. J. Immunol. 149: 989-997.
42. Cid, J., R. Aguinaco, R. Sánchez, G. García-Pardo, and A. Llorente. 2010. Neutrophil CD64 expression as marker of bacterial infection: a systematic review and meta-analysis. J. Infect. 60: 313-319.
43. Woof, J. M., and D. R. Burton. 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 4: 89-99. (Pubitemid 38209203)
44. Metes, D., C. Galatiuc, I. Moldovan, P. A. Morel, W. H. Chambers, A. B. DeLeo, H. Rabinowich, R. Schall, T. L. Whiteside, A. Sulica, et al. 1994. Expression and function of Fc gamma RII on human natural killer cells. Nat. Immun. 13: 289-300.
45. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
46. van Mirre, E., W. B. Breunis, J. Geissler, C. E. Hack, M. de Boer, D. Roos, and T. W. Kuijpers. 2006. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgammaRII (CD32), is stable over time and unaffected by cytokines. Blood 108: 584-590. (Pubitemid 44063467)
47. Rothberg, M. B., S. D. Haessler, and R. B. Brown. 2008. Complications of viral influenza. Am. J. Med. 121: 258-264. (Pubitemid 351417852)
48. Jakus, Z., T. Németh, J. S. Verbeek, and A. Mócsai. 2008. Critical but overlapping role of FcgammaRIII and FcgammaRIV in activation of murine neutrophils by immobilized immune complexes. J. Immunol. 180: 618-629.
49. Baumann, U., J. Köhl, T. Tschernig, K. Schwerter-Strumpf, J. S. Verbeek, R. E. Schmidt, and J. E. Gessner. 2000. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J. Immunol. 164: 1065-1070.
50. Bestebroer, J., P. C. Aerts, S. H. Rooijakkers, M. K. Pandey, J. Köhl, J. A. van Strijp, and C. J. de Haas. 2010. Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell. Microbiol. 12: 1506-1516.
51. van den Berg, S., M. G. Bowden, T. Bosma, G. Buist, J. M. van Dijl, W. J. van Wamel, C. P. de Vogel, A. van Belkum, and I. A. Bakker-Woudenberg. 2011. A multiplex assay for the quantification of antibody responses in Staphylococcus aureus infections in mice. J. Immunol. Methods 365: 142-148.
52. Burnside, K., A. Lembo, M. I. Harrell, J. A. Klein, J. Lopez-Guisa, A. M. Siegesmund, T. R. Torgerson, M. Oukka, D. M. Molina, and L. Rajagopal. 2012. Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. J. Infect. Dis. 206: 1734-1744.